O-GlcNAcylation-mediated glycolytic reprogramming of CD4+ T cells contributes to type H vessel impairment in diabetic osteoporosis
Cellular Signalling · 2026-10 · 146 · 112694
DOI: 10.1016/j.cellsig.2026.112694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026-10. Verfasst von Yujun Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong key Laboratory of Oral…. Hauptthemen laut MEDLINE: Glycolysis, CD4-Positive T-Lymphocytes, Osteoporosis. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Taishan Scholar Foundation of Shandong Province, Shandong Province Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Diabetic osteoporosis (DOP) is a metabolic bone disease characterized by skeletal fragility and impaired angiogenesis-osteogenesis coupling, in which type H vessel impairment has emerged as an important pathological feature. While adaptive immunity is known to regulate bone homeostasis, the immunometabolic mechanisms driving vascular dysfunction in DOP remain elusive. Here, we investigated whether pathological metabolic reprogramming of CD4+ T cells is linked to type H vessel impairment in DOP. CD4+ T cells from DOP mice exhibited enhanced glycolytic activation accompanied by increased hexokinase 2 (HK2) expression and elevated O-GlcNAcylation. In vitro, high glucose and palmitic acid (HGPA) treatment was associated with increased HK2 O-GlcNAcylation, HK2 stabilization, mitochondrial localization, and enhanced glycolytic activity in CD4+ T cells. These metabolic alterations were accompanied by senescence-associated and pro-inflammatory phenotypes, including upregulation of P53, P16, PD-1, IL-6, and IL-17 A, as well as enhanced T helper 17 (Th17) polarization. Co-culture experiments showed that HGPA-treated CD4+ T cells were associated with impaired endothelial viability, migration, tube formation, and reduced VEGFA/VEGFR2 expression. Pharmacological inhibition of O-GlcNAcylation or glycolysis partially attenuated CD4+ T cell dysfunction and improved endothelial angiogenic function. Collectively, these findings suggest that O-GlcNAcylation-associated HK2 glycolytic activation may contribute to CD4+ T cell dysfunction and type H vessel impairment in DOP. Targeting this immunometabolic pathway may represent a potential therapeutic strategy for diabetic skeletal complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental…
- Ultrastructure of Hard Tissue, Graduate School of Dental Medicine, Faculty of Dental Medicine, Hokkaido University, Sapporo, Japan. Electronic address: hasegawa@den.hokudai.ac.jp.
Förderung
- Taishan Scholar Foundation of Shandong Province
- Shandong Province Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Jiang, Y., Dai, Y., Li, X., Cui, Y., Liu, H., Hasegawa, T., & Li, M. (2026). O-GlcNAcylation-mediated glycolytic reprogramming of CD4+ T cells contributes to type H vessel impairment in diabetic osteoporosis. Cellular Signalling, 146, 112694. https://doi.org/10.1016/j.cellsig.2026.112694
Vancouver
Jiang Y, Dai Y, Li X, Cui Y, Liu H, Hasegawa T, et al. O-GlcNAcylation-mediated glycolytic reprogramming of CD4+ T cells contributes to type H vessel impairment in diabetic osteoporosis. Cellular Signalling. 2026;146:112694. doi:10.1016/j.cellsig.2026.112694
BibTeX
@article{Jiang2026,
author = {Jiang, Yujun and Dai, Yaling and Li, Xiaolin and Cui, Yajun and Liu, Hongrui and Hasegawa, Tomoka and Li, Minqi},
title = {O-GlcNAcylation-mediated glycolytic reprogramming of CD4+ T cells contributes to type H vessel impairment in diabetic osteoporosis},
journal = {Cellular Signalling},
year = {2026},
volume = {146},
pages = {112694},
doi = {10.1016/j.cellsig.2026.112694}
}
EUVIMED